Rhabdomyosarcoma - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 72 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Rhabdomyosarcoma - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Rhabdomyosarcoma - Pipeline Review, H2 2014', provides an overview of the Rhabdomyosarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Rhabdomyosarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Rhabdomyosarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Rhabdomyosarcoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Rhabdomyosarcoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Rhabdomyosarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Rhabdomyosarcoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Rhabdomyosarcoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Rhabdomyosarcoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Rhabdomyosarcoma Overview 6
Therapeutics Development 7
Pipeline Products for Rhabdomyosarcoma - Overview 7
Pipeline Products for Rhabdomyosarcoma - Comparative Analysis 8
Rhabdomyosarcoma - Therapeutics under Development by Companies 9
Rhabdomyosarcoma - Therapeutics under Investigation by Universities/Institutes 10
Rhabdomyosarcoma - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Rhabdomyosarcoma - Products under Development by Companies 13
Rhabdomyosarcoma - Products under Investigation by Universities/Institutes 14
Rhabdomyosarcoma - Companies Involved in Therapeutics Development 15
Arisaph Pharmaceuticals, Inc. 15
Bellicum Pharmaceuticals, Inc. 16
Celgene Corporation 17
Eisai Co., Ltd. 18
GlaxoSmithKline plc 19
Neotropix, Inc. 20
Novartis AG 21
Rhabdomyosarcoma - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 26
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Drug Profiles 32
ARI-4175 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cell Therapy for GD2 Expressing Solid Tumors - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
celyvir - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3, and NY-ESO-1 for Oncology - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
E-7438 - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
everolimus - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NTX-010 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
paclitaxel albumin bound - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
pazopanib hydrochloride - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Rhabdomyosarcoma - Recent Pipeline Updates 56
Rhabdomyosarcoma - Dormant Projects 69
Rhabdomyosarcoma - Discontinued Products 70
Appendix 71
Methodology 71
Coverage 71
Secondary Research 71
Primary Research 71
Expert Panel Validation 71
Contact Us 72
Disclaimer 72

List of Tables
Number of Products under Development for Rhabdomyosarcoma, H2 2014 7
Number of Products under Development for Rhabdomyosarcoma - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Clinical Stage Development, H2 2014 11
Comparative Analysis by Early Stage Development, H2 2014 12
Products under Development by Companies, H2 2014 13
Products under Investigation by Universities/Institutes, H2 2014 14
Rhabdomyosarcoma - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2014 15
Rhabdomyosarcoma - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2014 16
Rhabdomyosarcoma - Pipeline by Celgene Corporation, H2 2014 17
Rhabdomyosarcoma - Pipeline by Eisai Co., Ltd., H2 2014 18
Rhabdomyosarcoma - Pipeline by GlaxoSmithKline plc, H2 2014 19
Rhabdomyosarcoma - Pipeline by Neotropix, Inc., H2 2014 20
Rhabdomyosarcoma - Pipeline by Novartis AG, H2 2014 21
Assessment by Monotherapy Products, H2 2014 22
Number of Products by Stage and Target, H2 2014 25
Number of Products by Stage and Mechanism of Action, H2 2014 27
Number of Products by Stage and Route of Administration, H2 2014 29
Number of Products by Stage and Molecule Type, H2 2014 31
Rhabdomyosarcoma Therapeutics - Recent Pipeline Updates, H2 2014 56
Rhabdomyosarcoma - Dormant Projects, H2 2014 69
Rhabdomyosarcoma - Discontinued Products, H2 2014 70